Search

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics Announces Initiation of EMBARK, a Global Pivotal Study of SRP-9001, a Gene Therapy for the Treatment of Duchenne Muscular Dystrophy
Sarepta Therapeutics Opens Genetic Therapies Center of Excellence in Columbus, Ohio
Sarepta Therapeutics’ SRP-9001 Shows Sustained Functional Improvements in Multiple Studies of Patients with Duchenne
Sarepta Therapeutics Announces Preliminary Financial Results for the Third Quarter Ended September 30, 2021
Sarepta Therapeutics Announces Proposed $500,000,000 Public Offering of Common Stock
Sarepta Therapeutics Announces Pricing of $500 Million Public Offering of Common Stock
Sarepta Therapeutics to Announce Third Quarter 2021 Financial Results and Recent Corporate Developments on November 3, 2021
Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sarepta Therapeutics to Present at Upcoming Investor Conferences